Effectiveness of CRD-740 in Heart Failure

Summary

This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF. Part B of the study was not conducted in favor of redesigned new studies.

Timeline

Start

2022-05-26

Primary completion

2023-05-02

Completion

2023-07-25

Publications

• Udelson JE, Belohlavek J, Dukat A, Ezekowitz J, Goland S, Merkely B, O'Meara E, Petrie MC, Ponikowski P, Senni M, Tokmakova M, Vardeny O, Claggett B, Moore E, Savard M, McKellar H, Surks HK, Solomon SD, McMurray JJV. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. JACC Heart Fail. 2026 Jan;14(1):102706. doi: 10.1016/j.jchf.2025.102706. Epub 2025 Oct 31.

Drugs

Indications